255 related articles for article (PubMed ID: 18618304)
1. Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice.
Del Signore SJ; Amante DJ; Kim J; Stack EC; Goodrich S; Cormier K; Smith K; Cudkowicz ME; Ferrante RJ
Amyotroph Lateral Scler; 2009 Apr; 10(2):85-94. PubMed ID: 18618304
[TBL] [Abstract][Full Text] [Related]
2. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice.
Ryu H; Smith K; Camelo SI; Carreras I; Lee J; Iglesias AH; Dangond F; Cormier KA; Cudkowicz ME; Brown RH; Ferrante RJ
J Neurochem; 2005 Jun; 93(5):1087-98. PubMed ID: 15934930
[TBL] [Abstract][Full Text] [Related]
3. Uridine ameliorates the pathological phenotype in transgenic G93A-ALS mice.
Amante DJ; Kim J; Carreiro ST; Cooper AC; Jones SW; Li T; Moody JP; Edgerly CK; Bordiuk OL; Cormier K; Smith K; Ferrante RJ; Rusche J
Amyotroph Lateral Scler; 2010 Dec; 11(6):520-30. PubMed ID: 20565334
[TBL] [Abstract][Full Text] [Related]
4. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis.
Petri S; Kiaei M; Kipiani K; Chen J; Calingasan NY; Crow JP; Beal MF
Neurobiol Dis; 2006 Apr; 22(1):40-9. PubMed ID: 16289867
[TBL] [Abstract][Full Text] [Related]
5. Creatine supplementation and riluzole treatment provide similar beneficial effects in copper, zinc superoxide dismutase (G93A) transgenic mice.
Snow RJ; Turnbull J; da Silva S; Jiang F; Tarnopolsky MA
Neuroscience; 2003; 119(3):661-7. PubMed ID: 12809687
[TBL] [Abstract][Full Text] [Related]
6. Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model.
Waibel S; Reuter A; Malessa S; Blaugrund E; Ludolph AC
J Neurol; 2004 Sep; 251(9):1080-4. PubMed ID: 15372249
[TBL] [Abstract][Full Text] [Related]
7. Efficient three-drug cocktail for disease induced by mutant superoxide dismutase.
Kriz J; Gowing G; Julien JP
Ann Neurol; 2003 Apr; 53(4):429-36. PubMed ID: 12666110
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 study of sodium phenylbutyrate in ALS.
Cudkowicz ME; Andres PL; Macdonald SA; Bedlack RS; Choudry R; Brown RH; Zhang H; Schoenfeld DA; Shefner J; Matson S; Matson WR; Ferrante RJ;
Amyotroph Lateral Scler; 2009 Apr; 10(2):99-106. PubMed ID: 18688762
[TBL] [Abstract][Full Text] [Related]
9. Electrophysiologic biomarkers for assessing disease progression and the effect of riluzole in SOD1 G93A ALS mice.
Li J; Sung M; Rutkove SB
PLoS One; 2013; 8(6):e65976. PubMed ID: 23762454
[TBL] [Abstract][Full Text] [Related]
10. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis.
Gurney ME; Fleck TJ; Himes CS; Hall ED
Neurology; 1998 Jan; 50(1):62-6. PubMed ID: 9443458
[TBL] [Abstract][Full Text] [Related]
11. Life span extension and reduced neuronal death after weekly intraventricular cyclosporin injections in the G93A transgenic mouse model of amyotrophic lateral sclerosis.
Karlsson J; Fong KS; Hansson MJ; Elmér E; Csiszar K; Keep MF
J Neurosurg; 2004 Jul; 101(1):128-37. PubMed ID: 15255263
[TBL] [Abstract][Full Text] [Related]
12. Riluzole does not improve lifespan or motor function in three ALS mouse models.
Hogg MC; Halang L; Woods I; Coughlan KS; Prehn JHM
Amyotroph Lateral Scler Frontotemporal Degener; 2018 Aug; 19(5-6):438-445. PubMed ID: 29221425
[TBL] [Abstract][Full Text] [Related]
13. Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis.
Klivenyi P; Kiaei M; Gardian G; Calingasan NY; Beal MF
J Neurochem; 2004 Feb; 88(3):576-82. PubMed ID: 14720207
[TBL] [Abstract][Full Text] [Related]
14. A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis.
Morrison BM; Lachey JL; Warsing LC; Ting BL; Pullen AE; Underwood KW; Kumar R; Sako D; Grinberg A; Wong V; Colantuoni E; Seehra JS; Wagner KR
Exp Neurol; 2009 Jun; 217(2):258-68. PubMed ID: 19285073
[TBL] [Abstract][Full Text] [Related]
15. The lipophilic metal chelators DP-109 and DP-460 are neuroprotective in a transgenic mouse model of amyotrophic lateral sclerosis.
Petri S; Calingasan NY; Alsaied OA; Wille E; Kiaei M; Friedman JE; Baranova O; Chavez JC; Beal MF
J Neurochem; 2007 Aug; 102(3):991-1000. PubMed ID: 17630988
[TBL] [Abstract][Full Text] [Related]
16. An outcome study of riluzole in amyotrophic lateral sclerosis--a population-based study in Ireland, 1996-2000.
Traynor BJ; Alexander M; Corr B; Frost E; Hardiman O
J Neurol; 2003 Apr; 250(4):473-9. PubMed ID: 12700914
[TBL] [Abstract][Full Text] [Related]
17. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study.
Graf M; Ecker D; Horowski R; Kramer B; Riederer P; Gerlach M; Hager C; Ludolph AC; Becker G; Osterhage J; Jost WH; Schrank B; Stein C; Kostopulos P; Lubik S; Wekwerth K; Dengler R; Troeger M; Wuerz A; Hoge A; Schrader C; Schimke N; Krampfl K; Petri S; Zierz S; Eger K; Neudecker S; Traufeller K; Sievert M; Neundörfer B; Hecht M;
J Neural Transm (Vienna); 2005 May; 112(5):649-60. PubMed ID: 15517433
[TBL] [Abstract][Full Text] [Related]
18. Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model.
Feng HL; Leng Y; Ma CH; Zhang J; Ren M; Chuang DM
Neuroscience; 2008 Aug; 155(3):567-72. PubMed ID: 18640245
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological treatment of ALS.
Münch C; Ludolph AC
Neurol Neurochir Pol; 2001; 35(1 Suppl):41-50. PubMed ID: 11732279
[TBL] [Abstract][Full Text] [Related]
20. [Cotreatment of amyotrophic lateral sclerosis patients].
Iwasaki Y; Ikeda K
Rinsho Shinkeigaku; 1999 Dec; 39(12):1253-5. PubMed ID: 10791091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
